<DOC>
	<DOC>NCT00152516</DOC>
	<brief_summary>To allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies N01009(NCT00105040)/N01103(NCT00175890) or by direct enrollment) open-label levetiracetam treatment, continue studying cognition and behavior in children, and continue collection of safety/efficacy data.</brief_summary>
	<brief_title>Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Pediatric patients with partial onset seizures, with 1 to 2 antiepileptic drugs (AEDS), with participation in previous levetiracetam pediatric studies (N01009 or N01103) or direct enrollment, for whom levetiracetam treatment will be of possible benefit Patients on a ketogenic diet Seizures too close together to accurately count Pseudoseizures Status epilepticus 1 month prior Visit 1 Current diagnosis of LennoxGastaut Syndrome or epilepsy secondary to a progressing cerebral disease will be excluded from the study.</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Keppra</keyword>
</DOC>